AGIO Projected Dividend Yield
Agios Pharmaceuticals Inc ( NASDAQ : AGIO )Agios Pharmaceuticals is a biopharmaceutical company focused on improving patients' lives in the field of cellular metabolism and adjacent areas of biology, with the goal of creating molecule medicines for genetically defined diseases (GDD). The lead product in its GDD, portfolio, PYRUKYND® (mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the potential treatment of hemolytic anemias. Co. is evaluating PYRUKYND® for the treatment of a- and B-thalassemia and sickle cell disease (SCD). Co. is also developing AG-946, a PK activator, for the potential treatment of hemolytic anemias and other indications, including SCD. 20 YEAR PERFORMANCE RESULTS |
AGIO Dividend History Detail AGIO Dividend News AGIO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |